Fig. 4: Time from randomisation to progression on next line of therapy (PFS2) from the KEYNOTE-177 trial: Pembrolizumab versus chemotherapy for microsatellite instability-high advanced colorectal cancer.
From: Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group
Abstract 6 presented by Dr K-K Shiu at 2021 ASCO Gastrointestinal Cancers Symposium [41]. Reproduction with the permission of the author.
